To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 27, 2019

Today's Rundown

Featured Story

Days after its $63M boost, Imara gains former Pfizer rare disease executive as CMO

Sickle cell disease biotech Imara has nabbed Pfizer’s clinical rare disease lead Willem H. Scheele, M.D., as its new chief medical officer.

Top Stories

GenFit gets $135M Nasdaq IPO for NASH, PBC hopes

Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO.

ProQR spins out skin disease drug into nonprofit-backed startup

ProQR Therapeutics has spun out its early-phase oligonucleotide treatment for a rare inherited skin disorder to form a new company. The spinout, Wings Therapeutics, starts life with a phase 1/2 asset and funding from a disease-focused nonprofit.

Ono pumps cash into U.K. immuno-oncology R&D effort

Ono Pharmaceutical has formed an immuno-oncology pact with Cancer Research UK and LifeArc. The deal gives Ono the chance to license antibodies and small molecules advanced by its partners.

Treating heart failure by targeting fat metabolism

By burning fats and glucose, our hearts get the energy necessary to function well. Scientists at Ohio State University have identified a compound that's key in fat metabolism but that falls when the heart becomes stressed. Restoring it could reduce the risk of heart failure, they found.

Novartis snags blockbuster OK for secondary progressive multiple sclerosis drug Mayzent

Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis. The next challenge? Getting doctors to diagnose it.

Resources

[Whitepaper] Systolic Heart Failure: Real-World Study Using Electronic Health Records

Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care.

[Article] Are you ready for 2008 Microsoft SQL and Windows Servers end of life?

Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage.

[Whitepaper] Better Market Intelligence With Smart Search

From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve.

[Case Study] TriCore Reference Laboratories Transforms to Clinical Lab 2.0 Model

Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories.

[Whitepaper] Accelerating Clinical Trials through Access to Real-World Patient Data

Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs.

[Whitepaper] The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing.

[Whitepaper] How changes in drug substance processes can affect formulation

Download this whitepaper to learn more.

[Research] Maximize Pharma Marketing ROI with Digital HCP Engagement

Which HCP Touchpoints and channels are yielding the best results in today’s digital world?

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events